TY - JOUR
T1 - Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme
AU - Aljunid, Syed
AU - Maimaiti, Namaitijiang
AU - Ahmed, Zafar
AU - Muhammad Nur, Amrizal
AU - Md Isa, Zaleha
AU - Azmi, Soraya
AU - Sulong, Saperi
N1 - Funding Information:
Source of financial support: The preparation of this article was funded by a grant from GlaxoSmithKline Pty Ltd. However, data collection for the study, model inputs, and decisions related to technical aspects of the project and content of the manuscript are the sole responsibility of the authors. Soraya Azmi is a paid consultant by the International Case-Mix and Clinical Coding Centre UKM Medical Centre, Faculty of Medicine, Universiti Kebangsaan Malaysia.
PY - 2014/5/21
Y1 - 2014/5/21
N2 - Objective: To assess the cost-effectiveness of introducing pneumococcal polysaccharide and nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in the National Immunization Programme of Malaysia. This study compared introducing PHiD-CV (10 valent vaccine) with current no vaccination, as well as against the alternative 13-valent pneumococcal conjugate vaccine (PCV13). Methods: A lifetime Markov cohort model was adapted using national estimates of disease burden, outcomes of pneumococcal disease, and treatment costs of disease manifestations including pneumonia, acute otitis media, septicemia, and meningitis for a hypothetical birth cohort of 550,000 infants. Clinical information was obtained by review of medical records from four public hospitals in Malaysia from the year 2008 to 2009. Inpatient cost from the four study hospitals was obtained from a diagnostic-related group-based costing system. Outpatient cost was estimated using clinical pathways developed by an expert panel. The perspective assessed was that of the Ministry of Health, Malaysia. Results: The estimated disease incidence was 1.2, 3.7, 70, and 6.9 per 100,000 population for meningitis, bacteremia, pneumonia, and acute otitis media, respectively. The Markov model predicted medical costs of Malaysian ringgit (RM) 4.86 billion (US $1.51 billion) in the absence of vaccination. Vaccination with PHiD-CV would be highly cost-effective against no vaccination at RM30,290 (US $7,407) per quality-adjusted life-year gained. On comparing PHiD-CV with PCV13, it was found that PHiD-CV dominates PCV13, with 179 quality-adjusted life-years gained while saving RM35 million (US $10.87 million). Conclusions: It is cost-effective to incorporate pneumococcal vaccination in the National Immunization Programme of Malaysia. Our model suggests that PHiD-CV would be more cost saving than PCV13 from the perspective of the Ministry of Health of Malaysia.
AB - Objective: To assess the cost-effectiveness of introducing pneumococcal polysaccharide and nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in the National Immunization Programme of Malaysia. This study compared introducing PHiD-CV (10 valent vaccine) with current no vaccination, as well as against the alternative 13-valent pneumococcal conjugate vaccine (PCV13). Methods: A lifetime Markov cohort model was adapted using national estimates of disease burden, outcomes of pneumococcal disease, and treatment costs of disease manifestations including pneumonia, acute otitis media, septicemia, and meningitis for a hypothetical birth cohort of 550,000 infants. Clinical information was obtained by review of medical records from four public hospitals in Malaysia from the year 2008 to 2009. Inpatient cost from the four study hospitals was obtained from a diagnostic-related group-based costing system. Outpatient cost was estimated using clinical pathways developed by an expert panel. The perspective assessed was that of the Ministry of Health, Malaysia. Results: The estimated disease incidence was 1.2, 3.7, 70, and 6.9 per 100,000 population for meningitis, bacteremia, pneumonia, and acute otitis media, respectively. The Markov model predicted medical costs of Malaysian ringgit (RM) 4.86 billion (US $1.51 billion) in the absence of vaccination. Vaccination with PHiD-CV would be highly cost-effective against no vaccination at RM30,290 (US $7,407) per quality-adjusted life-year gained. On comparing PHiD-CV with PCV13, it was found that PHiD-CV dominates PCV13, with 179 quality-adjusted life-years gained while saving RM35 million (US $10.87 million). Conclusions: It is cost-effective to incorporate pneumococcal vaccination in the National Immunization Programme of Malaysia. Our model suggests that PHiD-CV would be more cost saving than PCV13 from the perspective of the Ministry of Health of Malaysia.
KW - 13-valent pneumococcal conjugate vaccine
KW - Cost-effectiveness
KW - Malaysia
KW - Nontypeable Haemophilus influenzae
KW - PHiD-CV
KW - Pneumococcal conjugate vaccine
KW - Pneumococcal protein-D conjugate vaccine
KW - Streptococcus pneumoniae
UR - http://www.scopus.com/inward/record.url?scp=84901245721&partnerID=8YFLogxK
U2 - 10.1016/j.vhri.2014.04.008
DO - 10.1016/j.vhri.2014.04.008
M3 - Article
AN - SCOPUS:84901245721
SN - 2212-1099
VL - 3
SP - 146
EP - 155
JO - Value in Health Regional Issues
JF - Value in Health Regional Issues
IS - 1
ER -
